Table 1 Baseline disease and demographic characteristics in analysis population
Angiotensin II > 5 ng kg−1 min−1 (n = 84) | Angiotensin II ≤ 5 ng kg−1 min−1 (n = 79) | |
|---|---|---|
Age, n (%) | ||
< 65 years | 47 (56.0) | 43 (54.4) |
≥ 65 years | 37 (44.0) | 36 (45.6) |
Sex, n (%) | ||
Male | 47 (56.0) | 45 (57.0) |
Female | 37 (44.0) | 34 (43.0) |
Race, n (%) | ||
White | 69 (82.1) | 66 (83.5) |
Nonwhite | 15 (17.9) | 13 (16.5) |
Body mass index, n (%) | n = 83 | n = 78 |
< 18.5 kg/m2 | 3 (3.6) | 4 (5.1) |
≥ 18.5 to < 25 kg/m2 | 22 (26.5) | 21 (26.9) |
≥ 25 to < 30 kg/m2 | 20 (24.1) | 22 (28.2) |
≥ 30 kg/m2 | 38 (45.8) | 31 (39.7) |
Geographic region, n (%) | ||
Australia/New Zealand | 17 (20.2) | 11 (13.9) |
Europe | 10 (11.9) | 9 (11.4) |
USA/Canada | 57 (67.9) | 59 (74.7) |
Albumin, n (%) | n = 78 | n = 76 |
< 2.5 g/dL | 56 (71.8) | 47 (61.8) |
≥ 2.5 g/dL | 22 (28.2) | 29 (38.2) |
Cause of shock, n (%) | ||
Sepsis | 68 (81.0) | 59 (74.7) |
Likely sepsis | 8 (9.5) | 12 (15.2) |
Vasoplegia | 3 (3.6) | 7 (8.9) |
Other | 5 (6.0) | 1 (1.3) |
Baseline MAP,* n (%) | ||
< 65 mmHg | 37 (44.0) | 15 (19.0) |
≥ 65 mmHg | 47 (56.0) | 64 (81.0) |
Baseline APACHE II score, n (%) | ||
≤ 30 | 54 (64.3) | 51 (64.6) |
31–40 | 29 (34.5) | 21 (26.6) |
≥ 41 | 1 (1.2) | 7 (8.9) |
Norepinephrine-equivalent dose 6 h before randomization, mean, µg/kg/min (SD) | 0.52 (0.301) | 0.45 (0.377) |
Baseline norepinephrine-equivalent dose,* n (%) | ||
< 0.5 µg/kg/min | 50 (59.5) | 67 (84.8) |
≥ 0.5 µg/kg/min | 34 (40.5) | 12 (15.2) |
Baseline angiotensin I,* n (%) | n = 74 | n = 71 |
Mean (SD) | 678.9 (810.8) | 618.0 (1332.5) |
Median (range) | 346.0 (10.5–3730.0) | 164 (10.5–9180.0) |
< 72.3 pg/mL | 12 (16.2) | 24 (33.8) |
72.3 to < 253 pg/mL | 14 (18.9) | 19 (26.8) |
253 to < 676 pg/mL | 25 (33.8) | 14 (19.7) |
≥ 676 pg/mL | 23 (31.1) | 14 (19.7) |
Baseline angiotensin II,* n (%) | n = 74 | n = 70 |
Mean (SD) | 420.8 (680.3) | 128.3 (199.1) |
Median (range) | 157.5 (10.5–3340.0) | 61.3 (10.5–1090.0) |
< 23.85 pg/mL | 14 (18.9) | 21 (30.0) |
23.85 to < 83.75 pg/mL | 11 (14.9) | 21 (30.0) |
83.75 to < 299.5 pg/mL | 25 (33.8) | 21 (30.0) |
≥ 299.5 pg/mL | 24 (32.4) | 7 (10.0) |
Exposure to angiotensin-converting enzyme inhibitors | 7 (8.3) | 8 (10.1) |
Exposure to angiotensin II receptor blockers | 9 (10.7) | 2 (2.5) |
Radiographic finding of ARDS | 23 (27.4) | 17 (21.5) |
Cardiac index (L/min/m2) | n = 36 | n = 33 |
Mean (SD) | 3.5 (1.07) | 3.1 (0.73) |
Median (range) | 3.1 (2.3–6.4) | 3.0 (2.1–5.4) |
ScvO2 (%) | n = 59 | n = 61 |
Mean (SD) | 78.2 (8.14) | 77 (9.64) |
Median (range) | 79.0 (53–99) | 75.9 (45–99) |
Central venous pressure (mmHg) | n = 64 | n = 62 |
Mean (SD) | 14.3 (5.8) | 13.2 (4.1) |
Median (range) | 13.0 (5–35) | 12.0 (6–29) |
SOFA score | ||
Mean (SD) | 12.0 (2.8) | 11.5 (2.8) |
Median (range) | 12.0 (5–18) | 12.0 (5–18) |